Messenger RNA (mRNA) is a transformative biotechnology platform that uses synthetic RNA molecules to instruct human cells to produce specific proteins, enabling immune protection or therapeutic effects. Unlike traditional vaccines or biologics, mRNA-based products do not require live pathogens or complex cell-based manufacturing, offering faster design and scalable production.
The technology gained global validation through the rapid development and deployment of COVID-19 vaccines by Moderna and BioNTech/Pfizer, demonstrating the speed, adaptability, and commercial viability of mRNA platforms. Today, mRNA applications extend beyond infectious diseases into oncology, rare genetic disorders, respiratory diseases, and personalized medicine.
Advancements such as nucleoside modifications and lipid nanoparticle (LNP) delivery systems have significantly improved stability, cellular uptake, and immune response while minimizing adverse reactions. According to BIS Research, the global messenger RNA market was valued at $2,438.0 million in 2025 and is projected to reach $20,990.1 million by 2035, growing at a CAGR of 24.02% during the forecast period 2025-2035.
Download the complete TOC and Request Sample Report
• Growing incidence of infectious diseases such as influenza and RSV
• Clinical and commercial validation of mRNA COVID-19 vaccines
• Rapid development timelines compared to traditional biologics
• Expanding applications in oncology and rare genetic disorders
• Increasing public–private investments and strategic collaborations
• Advancements in lipid nanoparticle delivery technologies
• Rising demand for pandemic preparedness and adaptable vaccine platforms
The rising global burden of infectious diseases remains a major catalyst. For instance:
• Seasonal influenza causes 3–5 million severe cases and 290,000–650,000 deaths annually worldwide, necessitating adaptable vaccine solutions.
• Respiratory Syncytial Virus (RSV) leads to over 3.6 million hospitalizations and approximately 100,000 deaths annually in children under five.
mRNA platforms allow rapid updates to address viral mutations, offering a strong advantage over conventional vaccine approaches that require longer reformulation cycles.
• High manufacturing complexity across multi-step production processes
• Stringent cold-chain storage and distribution requirements
• Supply chain constraints for GMP-grade raw materials
• Scalability challenges in lipid nanoparticle formulation
• Regulatory evolution for novel RNA-based therapeutics
• Cost pressures in personalized oncology applications
• August 2025: Moderna received Health Canada approval for its updated Spikevax COVID-19 mRNA vaccine targeting the SARS-CoV-2 LP.8.1 variant for individuals aged six months and older ahead of the 2025–2026 vaccination season.
• August 2025: Pfizer and BioNTech’s COMIRNATY secured U.S. FDA approval for adults aged 65+ and high-risk individuals aged 5–64.
• April 2025: Ethris partnered with Lonza to develop room-temperature stable, spray-dried mRNA vaccine formulations for mucosal respiratory delivery.
• March 2025: Primrose Bio introduced Prima RNApols ExTend to enhance long-template mRNA manufacturing efficiency and reduce double-stranded RNA impurities.
• Oncology
• Infectious Disease
• Rare Genetic Disease
• Respiratory Disease
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest-of-Europe
• Asia-Pacific
o Japan
o China
o Rest-of-Asia-Pacific
• Rest of the World
• Expansion into personalized cancer vaccines
• Integration of mRNA with CRISPR-based gene editing technologies
• Development of thermostable and mucosal delivery formulations
• Increasing focus on combination therapies with immunotherapies
• Diversification beyond infectious diseases into rare genetic and autoimmune disorders
According to the Principal Analyst at BIS Research: “The mRNA market represents a strategically critical and high-growth segment within biotechnology, supported by the proven success of COVID-19 vaccines. Its flexibility, scalability, and rapid development cycle offer competitive advantages over conventional biologics. While manufacturing complexity and cold-chain logistics remain operational challenges, continuous innovation in lipid nanoparticle systems, gene editing integration, and personalized therapeutics will position mRNA as a transformative force in precision medicine through 2035.”
The market is projected to grow from $2,438.0 million in 2025 to $20,990.1 million by 2035, at a CAGR of 24.02% during 2025-2035.
Infectious diseases hold the largest share at 99.86% as of 2024, driven by COVID-19, influenza, and RSV vaccine development.
Prominent companies include:
• Arcturus Therapeutics Inc
• Moderna, Inc
• SK Bioscience Co., Ltd.
• Oncotelic Inc
• Sanofi
• Pfizer Inc.
• AstraZeneca
• CureVac SE
• GSK plc
• Abogen Biosciences
• Beam Therapeutics Inc
Opportunities lie in personalized oncology vaccines, CRISPR-enabled gene editing therapies, thermostable vaccine formulations, and expansion into rare genetic disorders.
BIS Research delivers in-depth market intelligence, strategic insights, and competitive benchmarking across biotechnology, advanced therapeutics, and next-generation healthcare platforms.
